Multiple Sclerosis News Today9d
Tysabri may reduce risk of disability progression in SPMS: Analysis
A significant benefit was observed with Tysabri over Rebif in delaying SPMS disability progression when therapeutic lag was ...
Multiple Sclerosis News Today11d
First-line Tysabri better at reducing MS relapse rates, healthcare use
Studies have shown that starting a high-efficacy DMT like Tysabri earlier in the disease course can also lead to less ...
pharmaphorum1d
First Tysabri biosimilar cleared by FDA for MS
Sandoz and Polpharma Biologics have become the first companies to get FDA approval for a biosimilar of Biogen's blockbuster multiple sclerosis therapy Tysabri, after overcoming a bid by Biogen to ...
pharmaphorum2y
Polpharma in pole position for biosimilar Tysabri in Europe
Polpharma Biologics has become the first company to file for approval in the EU of a biosimilar version of Biogen's blockbuster multiple sclerosis therapy Tysabri. The biotech – headquartered in ...